Login to Your Account

Cerecor Inc. closed the first tranche of a $32 million series B Monday with plans to advance CERC-301, its experimental adjunctive therapy for patients with severe major depressive disorder (MDD) who haven't adequately responded to other therapies and are considering suicide.

Restorgenex Corp., a public specialty biopharma built from four small biotechs on the shell of a defunct sports and entertainment promoter, has closed the fifth and final round of a $35.6 million private placement.

Just five months after raising about $94.8 million in a well-received initial public offering (IPO), Auspex Pharmaceuticals Inc. has priced a new follow-on offering expected to raise an additional $60.6 million to carry a new pivotal trial of its lead candidate, SD-809 (dutetrabenazine), in the movement disorder tardive dyskinesia and to support the company through at least the second quarter of 2016.
More FINANCINGS Headlines

Cast Your Vote

Has biotech’s bubble burst?: